Literature DB >> 12784972

Ribozyme therapy: RNA enzymes to the rescue.

Antony M Jose1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12784972      PMCID： PMC2588793     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN： 0044-0086


× No keyword cloud information.
  36 in total

Review 1.  Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.

Authors:  N Usman; L M Blatt
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  The structural basis of ribosome activity in peptide bond synthesis.

Authors:  P Nissen; J Hansen; N Ban; P B Moore; T A Steitz
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

Review 3.  Emerging clinical applications of RNA.

Authors:  Bruce A Sullenger; Eli Gilboa
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

4.  Substrate sequence effects on "hammerhead" RNA catalytic efficiency.

Authors:  M J Fedor; O C Uhlenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

5.  Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression.

Authors:  Wade Winkler; Ali Nahvi; Ronald R Breaker
Journal:  Nature       Date:  2002-10-16       Impact factor: 49.962

6.  The Tetrahymena ribozyme acts like an RNA restriction endonuclease.

Authors:  A J Zaug; M D Been; T R Cech
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

7.  Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site.

Authors:  A C Forster; R H Symons
Journal:  Cell       Date:  1987-07-03       Impact factor: 41.582

8.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.

Authors:  P A Pavco; K S Bouhana; A M Gallegos; A Agrawal; K S Blanchard; S L Grimm; K L Jensen; L E Andrews; F E Wincott; P A Pitot; R J Tressler; C Cushman; M A Reynolds; T J Parry
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

9.  Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.

Authors:  G Bauer; P Valdez; K Kearns; I Bahner; S F Wen; J A Zaia; D B Kohn
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

10.  A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

Authors:  F Wong-Staal; E M Poeschla; D J Looney
Journal:  Hum Gene Ther       Date:  1998-11-01       Impact factor: 5.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.